Top Markets
#1 SODAX SODAX +58.16%
#2 龙虾 (Lobster) 龙虾 (Lobster) +37.41%
#3 Cortex Cortex +32.76%
#4 DexNet DexNet +23.20%
#5 Pons Pons +21.75%
#6 Akedo Akedo +20.11%
#7 wojak wojak +18.55%
#8 MANTRA MANTRA +14.88%
#9 OpenEden OpenEden +14.07%
#10 APEX APEX +13.93%
Coin of the day
SODAX SODAX
設定
言語
日本
通貨
USD
テーマ
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
株式のランク #7141
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
株価
$40.39
最終同期: 2023-08-18
時価総額
$1.70B
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Chinook Therapeutics, Inc. (KDNY)

カテゴリー

Healthcare
Chinook Therapeutics, Inc.（KDNY）の収益
Aug 2026 時点の収益 TTM: 0
Chinook Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Chinook Therapeutics, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH